Want to see ASMB full AI Analyst Report?
ASMB Stock Chart & Stats
$29.24
-$0.45(-2.59%)
At close: 4:00 PM EST
$29.24
-$0.45(-2.59%)
Day’s Range― - ―
52-Week Range$16.90 - $39.71
Previous CloseN/A
Volume7.37K
Average Volume (3M)164.41K
Market Cap
$549.73M
Enterprise Value$355.18M
Total Cash (Recent Filing)$226.60M
Total Debt (Recent Filing)$2.49M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Aug 12, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding19,817,250
10 Day Avg. Volume178,321
30 Day Avg. Volume164,409
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)1.84
Price to Sales (P/S)5.27
P/FCF Ratio-9.26
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue5.00
Enterprise Value/Gross Profit6.47
Enterprise Value/Ebitda-56.73
Forecast
1Y Price Target
$46.00Price Target Upside57.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.68
Revenue Forecast (FY)$57.96M
Bulls Say, Bears Say
Bulls Say
Low-leverage Balance SheetA very low debt load and sizeable equity/assets give Assembly durable financial flexibility to fund clinical programs without near-term debt pressures. This reduces bankruptcy risk, supports multi-year R&D investment, and makes the company a more attractive partner for collaborations.
Completed $107.4M Equity FinancingA large, recent equity raise materially extends runway and funds planned clinical development. Institutional participation including a strategic healthcare investor signals external validation and reduces immediate fundraising pressure, enabling the company to advance trials and exploratory indications.
Pipeline Expansion For ABI-6250Broadening ABI-6250 into cholestatic liver diseases leverages mechanistic differentiation and addresses high unmet need, diversifying the pipeline. Planned Phase 2 timing and FDA pre-IND dialogue increase the program's strategic optionality and potential partner/licensing interest.
Bears Say
Sizable Cash BurnSustained negative operating and free cash flow at this magnitude requires recurring financing to fund operations. Continued burn increases reliance on equity markets or partnerships, raising dilution risk and potentially forcing prioritization of programs if capital conditions deteriorate.
Persistent UnprofitabilityOngoing negative margins reflect that the business is not yet self-sustaining and depends on clinical progress to generate future value. Prolonged unprofitability limits internal funding capacity, pressures returns on equity, and makes long-term viability contingent on successful trial outcomes or lucrative partnerships.
Volatile, Declining RevenueHighly volatile, sharply declining top-line indicates dependence on uneven collaboration/license payments rather than steady product revenues. This undermines predictability of funding and operational planning, increasing exposure to timing risk for milestone payments and capital markets.
Assembly Biosciences News
ASMB FAQ
What was Assembly Biosciences’s price range in the past 12 months?
Assembly Biosciences lowest stock price was $16.90 and its highest was $39.70 in the past 12 months.
What is Assembly Biosciences’s market cap?
Assembly Biosciences’s market cap is $549.73M.
When is Assembly Biosciences’s upcoming earnings report date?
Assembly Biosciences’s upcoming earnings report date is Aug 12, 2026 which is in 39 days.
How were Assembly Biosciences’s earnings last quarter?
Assembly Biosciences released its earnings results on May 07, 2026. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.65 by $0.11.
Is Assembly Biosciences overvalued?
According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued.
Does Assembly Biosciences pay dividends?
Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate is -0.73.
How many shares outstanding does Assembly Biosciences have?
Assembly Biosciences has 19,817,250 shares outstanding.
What happened to Assembly Biosciences’s price movement after its last earnings report?
Assembly Biosciences reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.65. Following the earnings report the stock price went down -3.847%.
Which hedge fund is a major shareholder of Assembly Biosciences?
Currently, no hedge funds are holding shares in ASMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Assembly Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.00 (57.32% Upside)
$46.00 (57.32% Upside)
Hedge Fund Trend
Decreased
By 9.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $674.3 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 3.8%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.70%
12-Months-Change
Fundamentals
Return on Equity
-4.21%
Trailing 12-Months
Asset Growth
137.85%
Trailing 12-Months
Company Description
Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
ASMB Stock 12 Month Forecast
Average Price Target
$46.00
▲(57.32% Upside)
Technical Analysis
Benitec Biopharma
―
Annexon Biosciences
―
Quantum-Si
―
Vor Biopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
27.13% Insiders
3.79% Mutual Funds
51.46% Other Institutional Investors
12.96% Public Companies and
Individual Investors